Tanvex BioPharma, Inc. (TPE: 6541)
Taiwan
· Delayed Price · Currency is TWD 68.50
+3.40 (5.22%)
Jan 20, 2025, 1:30 PM CST
Tanvex BioPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 40.96 | 61.41 | 22.4 | 5.41 | 0.3 | - | Upgrade
|
| Revenue Growth (YoY) | -32.00% | 174.11% | 314.43% | 1702.00% | - | - | Upgrade
|
| Cost of Revenue | 30.11 | 1.71 | 41.75 | 1.86 | 0.16 | - | Upgrade
|
| Gross Profit | 10.85 | 59.7 | -19.35 | 3.55 | 0.14 | - | Upgrade
|
| Selling, General & Admin | 340.77 | 453.71 | 234.74 | 219.21 | 239.12 | 328.04 | Upgrade
|
| Research & Development | 1,242 | 1,707 | 1,351 | 1,384 | 1,861 | 2,000 | Upgrade
|
| Operating Expenses | 1,583 | 2,160 | 1,586 | 1,603 | 2,100 | 2,328 | Upgrade
|
| Operating Income | -1,572 | -2,101 | -1,606 | -1,599 | -2,100 | -2,328 | Upgrade
|
| Interest Expense | -57.56 | -57.38 | -54.72 | -46.22 | -18.57 | -15.58 | Upgrade
|
| Interest & Investment Income | 30.31 | 29.04 | 9.6 | 3.14 | 18.66 | 62.8 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.57 | 1.32 | 12.48 | 7.16 | -5.63 | 6.27 | Upgrade
|
| Other Non Operating Income (Expenses) | -18.75 | 1.88 | 4.25 | 92.85 | 1.18 | 0.61 | Upgrade
|
| EBT Excluding Unusual Items | -1,610 | -2,126 | -1,634 | -1,542 | -2,104 | -2,274 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.83 | -2.87 | -7.21 | -0.94 | -0.27 | -0.14 | Upgrade
|
| Asset Writedown | -8.67 | -8.67 | - | - | - | - | Upgrade
|
| Other Unusual Items | -0.19 | 0.77 | - | - | - | - | Upgrade
|
| Pretax Income | -1,621 | -2,137 | -1,641 | -1,543 | -2,104 | -2,274 | Upgrade
|
| Income Tax Expense | 0.3 | 0.43 | 0.02 | 0.02 | 0.02 | 0.03 | Upgrade
|
| Net Income | -1,621 | -2,137 | -1,641 | -1,543 | -2,104 | -2,274 | Upgrade
|
| Net Income to Common | -1,621 | -2,137 | -1,641 | -1,543 | -2,104 | -2,274 | Upgrade
|
| Shares Outstanding (Basic) | 148 | 129 | 118 | 109 | 89 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 148 | 129 | 118 | 109 | 89 | 82 | Upgrade
|
| Shares Change (YoY) | 18.34% | 9.60% | 8.31% | 21.32% | 9.25% | 7.87% | Upgrade
|
| EPS (Basic) | -10.98 | -16.58 | -13.95 | -14.21 | -23.51 | -27.76 | Upgrade
|
| EPS (Diluted) | -10.98 | -16.58 | -13.95 | -14.21 | -23.51 | -27.76 | Upgrade
|
| Free Cash Flow | -1,380 | -1,505 | -1,427 | -1,417 | -1,854 | -1,988 | Upgrade
|
| Free Cash Flow Per Share | -9.35 | -11.67 | -12.14 | -13.05 | -20.71 | -24.27 | Upgrade
|
| Gross Margin | 26.49% | 97.22% | -86.36% | 65.67% | 47.67% | - | Upgrade
|
| Operating Margin | -3838.22% | -3420.80% | -7166.21% | -29581.65% | -699859.00% | - | Upgrade
|
| Profit Margin | -3958.87% | -3480.00% | -7325.17% | -28546.26% | -701412.00% | - | Upgrade
|
| Free Cash Flow Margin | -3370.12% | -2450.42% | -6370.97% | -26208.75% | -617884.67% | - | Upgrade
|
| EBITDA | -1,466 | -1,976 | -1,492 | -1,496 | -1,958 | -2,183 | Upgrade
|
| D&A For EBITDA | 105.91 | 124.89 | 113.22 | 102.84 | 141.87 | 144.7 | Upgrade
|
| EBIT | -1,572 | -2,101 | -1,606 | -1,599 | -2,100 | -2,328 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.